Exercise capacity: |
At 3-12 month follow-up |
14 |
1938 |
Standard mean difference, random effects model |
−0.11 (−0.35 to 0.13) |
60.91 |
13 |
<0.001 |
79 |
At 12-24 month follow-up |
4 |
1074 |
Standard mean difference, fixed effects model |
0.11 (−0.01 to 0.23) |
0.87 |
3 |
0.62 |
0 |
Blood pressure (mm Hg) at 3-12 month follow-up: |
Systolic |
9 |
1053 |
Mean difference, random effects model |
−0.51 (−4.63 to 3.61) |
23.01 |
7 |
0.002 |
70 |
Diastolic |
7 |
927 |
Mean difference, random effects model |
1.85 (0.74 to 2.96) |
7.97 |
6 |
0.24 |
25 |
Cholesterol (mmol/l) at 3-12 month follow-up: |
Total |
7 |
1019 |
Mean difference, random effects model |
0.13 (−0.05 to 0.31) |
13.33 |
6 |
0.04 |
55 |
High density lipoprotein |
5 |
793 |
Mean difference, fixed effects model |
−0.06 (−0.11 to −0.02) |
4.44 |
3 |
0.22 |
32 |
Low density lipoprotein |
4 |
324 |
Mean difference, fixed effects model |
0.15 (−0.01 to 0.31) |
6.53 |
4 |
0.16 |
39 |
Triglycerides |
4 |
328 |
Mean difference, random effects model |
0.15 (−0.11 to 0.41) |
7.58 |
3 |
0.06 |
60 |
Smoking |
5 |
922 |
Relative risk, fixed effects model |
1.02 (0.76 to 1.37) |
4.48 |
4 |
0.34 |
11 |
Completers |
10 |
1714 |
Risk ratio, fixed effects model |
1.00 (0.97 to 1.04) |
11.4 |
10 |
0.32 |
13 |
Mortality |
4 |
909 |
Relative risk, fixed effects model |
1.31 (0.65 to 2.66) |
1.00 |
3 |
0.80 |
0 |